Bogoievski and K1W1 help local biotech firm address US Covid surveillance market
Parnell-based company seek global manufacturing expansion of its antibody tests.
An investment led by former Morrison & Co chief executive Marko Bogoievski and Sir Stephen Tindall’s investment arm K1W1 into local biotech firm Pictor will see the Kiwis partner with a US laboratory to use its test that allows people to see what kind of antibodies they have in the fight against
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Subscribe Now
Monthly Premium Online Subscription
NZ$49.95 / monthly
Subscribe Now
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Subscribe Now
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Subscribe Now
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
